Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
Appointed director
|
|
PhaseBio Pharmaceuticals Inc (PHAS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/10/2022 |
4/A
| Humphries William D. (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc|
Txns:
| Granted 11,842 options to buy
@ $0.8419, valued at
$10k
Granted 2,538 restricted stock units
@ $0 |
|
| 05/20/2022 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 09/03/2021 |
4/A
| Arnold Susan Elizabeth (VP, Preclinical and Chem) has filed a Form 4 on PhaseBio Pharmaceuticals Inc|
Txns:
| Exercised 4,519 options to buy
@ $1.74, valued at
$7.9k
|
|
| 09/03/2021 |
4/A
| Sharp John P (CFO) has filed a Form 4 on PhaseBio Pharmaceuticals Inc|
Txns:
| Exercised 7,500 options to buy
@ $1.68, valued at
$12.6k
|
|
| 12/13/2018 |
4/A
| Mow Jonathan P (CEO) has filed a Form 4 on PhaseBio Pharmaceuticals Inc|
Txns:
| Bought 700 shares
@ $3.89, valued at
$2.7k
Bought 800 shares
@ $3.85, valued at
$3.1k
|
|
|
|